Since 2017, several new drugs have been approved for the treatment of AML, including FLT3 inhibitors, the CD33-directed antibodies and inhibitors of mutated isocitrate dehydrogenase (IDH) [1, 2]. Here, IDH2 is linked to acute myeloid leukemia.